Clinical Trials Logo

Filter by:
NCT ID: NCT05687201 Active, not recruiting - Clinical trials for Intracerebral Hemorrhage

Effect of Apolipoprotein E on the Prognosis of Patients With Intracerebral Hemorrhage

Start date: January 1, 2020
Phase:
Study type: Observational

The purpose of this observational study was to compare perihematomal edema and short-term prognosis in patients with intracerebral hemorrhage carrying the APOE-ε3 and APOE-ε4 genes. The main questions it aims to answer are: - Exploring whether patients carrying the ApoE-ε4 gene have more perifocal perihematomal edema after intracerebral hemorrhage than patients with the ApoE-ε3 gene. - ApoEε4 gene has worse short-term prognosis than ApoEε3 gene in intracerebral hemorrhage patients. All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.Some ICH patients were evaluated for Stereotactic minimally invasive surgery (sMIS) treatment by two experienced neurosurgeons.

NCT ID: NCT05687032 Active, not recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: February 24, 2023
Phase: Phase 4
Study type: Interventional

This is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from mainland China.

NCT ID: NCT05686876 Recruiting - Psoriatic Arthritis Clinical Trials

FAPI-PET/CT in Psoriatic Arthritis

Start date: November 1, 2022
Phase: Early Phase 1
Study type: Interventional

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease. Therefore, this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for disease activity assessment and follow-up of psoriatic arthritis than 18F-NAF PET/CT.

NCT ID: NCT05686863 Completed - Drug Effect Clinical Trials

Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.

NCT ID: NCT05686720 Not yet recruiting - Clinical trials for Advanced Triple Negative Breast Cancer

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of advanced triple-negative breast cancer.

NCT ID: NCT05686642 Recruiting - Clinical trials for Acute Ischemic Stroke

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Start date: April 6, 2023
Phase: Phase 2
Study type: Interventional

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

NCT ID: NCT05686629 Not yet recruiting - Clinical trials for Novel COVID-19-Infected Pneumonia

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.

NCT ID: NCT05686603 Completed - Acne Clinical Trials

Comparison of Picosecond Lasers vs. Ablative Fractional Er:YAG Lasers in Treating Atrophic Scar

Start date: April 12, 2022
Phase: N/A
Study type: Interventional

The 1064-nm Nd:YAG picosecond lasers using fractional micro-lens array (P-MLA) was a promising therapy for skin resurfacing. However, no studies have compared P-MLA with ablative fractional 2940-nm Er:YAG lasers (AF-Er) in treating atrophic acne scars. To evaluate the efficacy and safety of P-MLA and AF-Er for the treatment of atrophic acne scars, we performed a prospective, randomized, split-face, controlled trial. Thirty-one Asian patients underwent four consecutive sessions of randomized split-face treatment with P-MLA and AF-Fr at 4-week intervals.

NCT ID: NCT05686447 Recruiting - Multiple Myeloma Clinical Trials

Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis

Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

To provide a comprehensive MALDI-TOF mass spectrometry method for detecting, characterizing, and quantifying M-protein, and to track M-protein in a very sensitive and specific manner during patient treatment, providing a more precise test for diagnosing disease and monitoring patient response to treatment.

NCT ID: NCT05686434 Recruiting - NSCLC, Stage I Clinical Trials

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Start date: October 14, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).